NewAmsterdam Pharma Co N.V. (NAMS)

About NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma Co N.V. is a biopharmaceutical company developing therapies for cardiometabolic diseases, focusing on lowering low-density lipoprotein cholesterol (LDL-C). Its main product candidate, obicetrapib, is an oral CETP inhibitor designed to be used alone or in combination with ezetimibe to reduce LDL-C levels in patients at risk of cardiovascular disease who do not respond adequately to existing treatments. The company conducts clinical trials and plans to commercialize obicetrapib primarily for patients with atherosclerotic cardiovascular disease and familial hypercholesterolemia.

Snapshot

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

Peer comparison

Where NewAmsterdam Pharma’s fundamentals sit among the 198 pharmaceutical companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

NewAmsterdam Pharma’s revenue growth of -50.6% ranks in the 12th percentile of the 188 pharmaceutical companies reporting it.

1 reported insider purchase (code P) totaling $226,500 in the last 90 days, against 6 sales totaling $7.8M. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Reported non-derivative purchases and sales (codes P/S), which may be open-market or private. Excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Quarterly trend

Latest 8 quarters, from company XBRL filings on SEC EDGAR. A dotted underline marks a fourth-quarter figure we calculated from the full year and the first nine months. Revenue YoY is our calculation too: each quarter against the same quarter a year earlier.

Company facts

Selected SEC filings

Largest pharmaceutical peers

All pharmaceutical stocks →All Healthcare companies →